Rigel PharmaceuticalsRIGL
RIGL
About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Employees: 147
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
98% more capital invested
Capital invested by funds: $97.1M [Q2] → $193M (+$95.5M) [Q3]
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
2% more funds holding
Funds holding: 90 [Q2] → 92 (+2) [Q3]
0.36% more ownership
Funds ownership: 67.29% [Q2] → 67.65% (+0.36%) [Q3]
61% less call options, than puts
Call options by funds: $2.83M | Put options by funds: $7.22M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
17%
upside
Avg. target
$35
104%
upside
High target
$57
234%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
Cantor Fitzgerald Kristen Kluska 38% 1-year accuracy 40 / 105 met price target | 46%upside $25 | Neutral Maintained | 10 Dec 2024 |
B. Riley Securities Kalpit Patel 33% 1-year accuracy 3 / 9 met price target | 17%upside $20 | Neutral Maintained | 10 Dec 2024 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 80 / 385 met price target | 234%upside $57 | Buy Reiterated | 10 Dec 2024 |
Piper Sandler Allison Bratzel 82% 1-year accuracy 9 / 11 met price target | 35%upside $23 | Neutral Maintained | 14 Nov 2024 |
Citigroup Yigal Nochomovitz 28% 1-year accuracy 13 / 46 met price target | 187%upside $49 | Buy Maintained | 12 Nov 2024 |
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD SOUTH SAN FRANCISCO, Calif. , Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS).
Neutral
PRNewsWire
2 weeks ago
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
SOUTH SAN FRANCISCO, Calif. , Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS).
Positive
Zacks Investment Research
1 month ago
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 month ago
5 Relative Price Strength Options Available for Investors
RIGL, SYF, SKYW, ALNT and RSI are five stocks with explosive relative price strength.
Neutral
PRNewsWire
1 month ago
Rigel to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST).
Neutral
Seeking Alpha
1 month ago
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.30 per share a year ago.
Neutral
PRNewsWire
1 month ago
Rigel Reports Third Quarter 2024 Financial Results and Provides Business Update
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 million during the third quarter Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS to be presented at the 66th ASH Annual Meeting Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.
Neutral
PRNewsWire
1 month ago
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS - Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters highlighting data from their commercial and clinical-stage hematology-oncology portfolio at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, California and virtually.
Neutral
PRNewsWire
1 month ago
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024.
Charts implemented using Lightweight Charts™